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ORIGINAL INVESTIGATION
Regulation of diabetic cardiomyopathy 
by caloric restriction is mediated by intracellular 
signaling pathways involving ‘SIRT1 and PGC-1α’
Maayan Waldman1,2, Keren Cohen1,2, Dor Yadin1,2, Vadim Nudelman1, Dan Gorfil1, 
Michal Laniado‑Schwartzman3, Ran Kornwoski1, Dan Aravot1, Nader G. Abraham3, Michael Arad2† 
and Edith Hochhauser1,4*†
Abstract 
Background: Metabolic disorders such as obesity, insulin resistance and type 2 diabetes mellitus (DM2) are all linked 
to diabetic cardiomyopathy that lead to heart failure. Cardiomyopathy is initially characterized by cardiomyocyte 
hypertrophy, followed by mitochondrial dysfunction and fibrosis, both of which are aggravated by angiotensin. 
Caloric restriction (CR) is cardioprotective in animal models of heart disease through its catabolic activity and activa‑
tion of the expression of adaptive genes. We hypothesized that in the diabetic heart; this effect involves antioxidant 
defenses and is mediated by SIRT1 and the transcriptional coactivator PGC‑1α (Peroxisome proliferator‑activated 
receptor‑γ coactivator).
Methods: Obese Leptin resistant (db/db) mice characterized by DM2 were treated with angiotensin II (AT) for 
4 weeks to enhance the development of cardiomyopathy. Mice were concomitantly either on a CR diet or fed ad libi‑
tum. Cardiomyocytes were exposed to high levels of glucose and were treated with EX‑527 (SIRT1 inhibitor). Cardiac 
structure and function, gene and protein expression and oxidative stress parameters were analyzed.
Results: AT treated db/db mice developed cardiomyopathy manifested by elevated levels of serum glucose, choles‑
terol and cardiac hypertrophy. Leukocyte infiltration, fibrosis and an increase in an inflammatory marker (TNFα) and 
natriuretic peptides (ANP, BNP) gene expression were also observed. Oxidative stress was manifested by low SOD and 
PGC‑1α levels and an increase in ROS and MDA. DM2 resulted in ERK1/2 activation. CR attenuated all these deleteri‑
ous perturbations and prevented the development of cardiomyopathy. ERK1/2 phosphorylation was reduced in CR 
mice (p = 0.008). Concomitantly CR prevented the reduction in SIRT activity and PGC‑1α (p < 0.04). Inhibition of SIRT1 
activity in cardiomyocytes led to a marked reduction in both SIRT1 and PGC‑1α. ROS levels were significantly (p < 0.03) 
increased by glucose and SIRT1 inhibition.
Conclusion: In the current study we present evidence of the cardioprotective effects of CR operating through SIRT1 
and PGC‑1 α, thereby decreasing oxidative stress, fibrosis and inflammation. Our results suggest that increasing SIRT1 
and PGC‑1α levels offer new therapeutic approaches for the protection of the diabetic heart.
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Introduction
Diabetes mellitus type 2 (DM2) is a common metabolic 
disorder characterized by impaired glucose tolerance 
and is associated with excess cardiovascular morbidity 
and mortality [1, 2]. Diabetic cardiomyopathy is mani-
fested by increased cardiomyocyte stiffness and fibrotic 
changes. Progressive cardiac fibrosis found in diabetic 
cardiomyopathy and during pressure overload results in 
diastolic dysfunction leading to reduced myocardial con-
tractility, pulmonary congestion and, ultimately, heart 
failure [3, 4]. Despite its clinical significance, the patho-
physiologic basis of myocyte hypertrophy and stiffen-
ing as well as cardiac fibrosis in DM2 remains poorly 
understood [5, 6]. The primary factors that lead to car-
diomyocyte injury and dysfunction in diabetes comprise 
insulin resistance and hyperinsulinemia, hyperglyce-
mia, and elevated free fatty acids (FFA) leading to myo-
cardial lipotoxicity [7]. Secondary mediators include 
oxidative stress, mitochondrial dysfunction, abnormal 
intracellular calcium metabolism [8] and chronic inflam-
mation [9]. Angiotensin II (AT), the effector peptide of 
the renin-angiotensin system (RAS), is a potent vaso-
constrictor [10]. Cardiac AT synthesis is sufficient to 
trigger the development of cardiac hypertrophy [11]. 
While hypertensive doses of AT produce a more pro-
nounced hypertrophic response, angiotensin receptor 
type 1 (AT1R)-mediated signaling may induce cardiac 
hypertrophy independently of hypertension [12] by act-
ing as a cardiac growth factor and through induction of 
the “fetal” gene TGF-β as well as dysregulation of colla-
gen degrading matrix metalloproteinases (MMPs) [13, 
14]. AT upregulation exacerbates the cardiac phenotype 
of diabetic mice [15].
Caloric restriction (CR) is defined as a decrease in 
caloric intake without deprivation of essential nutrients. 
Observational studies of individuals voluntarily practic-
ing long-term CR suggest that it positively affects car-
diovascular disease risk factors [16, 17]. CR increases 
longevity and both delays and slows the progression of 
multiple age-related diseases in animal models of car-
diac disease [18, 19]. Adiponectin, which increased in 
the plasma after CR [20, 21], has been implicated in CR-
induced cardioprotection [20]. SIRT1, a redox-sensitive 
enzyme, is a member of a large family of class III his-
tone deacetylase (HDAC) [22, 23]. SIRT1 is a modulator 
of genetic stability by extending life span in yeast, flies, 
and worms, while its deletion shortens life span [24]. 
Concomitantly, SIRT1 regulates a wide variety of cellu-
lar processes including apoptosis/cell survival, endocrine 
signaling, chromatin remodeling, and gene transcription 
[25]. SIRT1 activation recapitulates many of the molecu-
lar events downstream of CR in vivo, including enhanc-
ing mitochondrial biogenesis through activation of 
Peroxisome proliferator-activated receptor gamma coac-
tivator 1-alpha (PGC-1α), improving metabolic signaling 
pathways, and blunting pro-inflammatory pathways [26, 
27]. This effect is partly mediated by an anti-oxidant pro-
tein superoxide dismutase (SOD) [28, 29]. We have previ-
ously reported that CR decreased inflammatory markers 
in the diabetic heart [30].
DM2 often coexists with hypertension and is associ-
ated with increased AT signaling. We developed a murine 
cardiomyopathy mouse model by further stressing the 
diabetic heart by AT [30], and hypothesized that CR will 
affect cardiac remodeling in these hearts through molec-
ular mechanisms related to anti-oxidative pathways. We 
identified SIRT1, and PGC-1α as the driving force behind 
the cardioprotective effect of CR.
Methods
Animal model
The animal experiments were approved by the Insti-
tutional Animal Care and Use Committee of Tel Aviv 
University (M-15-010). Homozygous db/db mice 
(C57BLKS/J-leprdb/leprdb) and their wild type (WT) lit-
termates were maintained in a pathogen-free facility on 
regular rodent chow with free access to water and 12-h 
light and dark cycles. Homozygous mice were verified by 
PCR. Male WT or db/db mice (12–14  weeks old) were 
used for the experiments. db/db mice develop mild car-
diomyopathy at an advanced age [2, 31]. To enhance 
development of heart disease and obtain a robust phe-
notype, mice were stressed by ATII as described in other 
cardiomyopathy models [12]. The AT administration 
is described below (“Angiotensin” section). Mice were 
divided into the following groups (n = 5–14 each in each 
group): WT (n = 10), WT + AT (n = 12), WT + AT + CR 
(n = 5), db/db (n = 14), db/db + AT(n = 14), db/
db + AT + CR (n = 8).
Echocardiography
Animals were lightly anesthetized by inhaling isoflu-
rane. The heart rate in all animals was maintained dur-
ing the recording at 450–500  b/m. Two-dimensional 
(2D) guided M-mode echocardiography was performed 
using an echocardiogram (Vevo 2100 Imaging System, 
VisualSonics, Toronto, Ontario, Canada) equipped with 
a 30-MHz linear transducer. The 2D mode in the par-
asternal long-axis view was used to monitor the heart. 
From this view, an M-mode cursor was positioned per-
pendicular to the interventricular septum and posterior 
wall of the left ventricle (LV) at the level of the papillary 
muscles. An M-mode image was obtained at a sweep 
speed of 100 mm/s. Left-ventricular end-diastolic dimen-
sions (LVEDD) and left-ventricular end-systolic chamber 
dimensions (LVESD) were measured. The percentage of 
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left-ventricular fractional shortening (FS) was calculated 
as [(LVEDD—LVESD)/LVEDD] × 100 [32, 33].
Angiotensin
Mice were anesthetized with 2% isoflurane and an ALZET 
osmotic pump (Durect Corp., Cupertino, CA, USA) was 
subcutaneously implanted into each mouse. The osmotic 
pumps infused angiotensin II (Sigma-Aldrich, St. Louis, 
MO, USA) at a rate of 1000 ng kg−1 min−1 for 4 weeks.
Blood pressure measurement
Systolic blood pressure (SBP) was measured at the end of 
the experiment in awake mice using a noninvasive com-
puterized tail-cuff system (Blood pressure pump, Life 
science instrument, CA, USA). Mice were placed in tem-
perature-controlled chambers (37  °C) and blood pres-
sures were recorded in 2–3 cycles of 10 measurements.
Biochemical measurement in the serum
Serum (200 µl) was collected and kept on ice until pro-
cessed. Glucose, cholesterol, triglycerides, aspartate 
transaminase (AST) and alanine transaminase (ALT) 
levels were determined in duplicate, using a commercial 
Olympus OSR6126 kit (Center Valley, PA, USA) accord-
ing to the manufacturer’s protocols [33].
Caloric restriction
Mice were housed in individual cages. Caloric restricted 
(CR) mice were fed 90% of their average caloric intake for 
2 weeks (10% restriction), followed by 65% of that for an 
additional 2  weeks (35% restriction). Experiments were 
conducted after the 4-week period as we have previously 
published [32].
Histopathology
Midventricular heart sections were fixed in 4% formalin, 
and then embedded in paraffin. Several transverse sec-
tions were cut from the paraffin-embedded samples and 
stained with Hematoxylin and Eosin. Sections from each 
heart were also stained with Masson trichrome for col-
lagen deposition [33, 34]. For each staining, slides from 3 
mice per group were analyzed.
Western blotting
Cardiac tissue (n = 4 in each group) was homogenized 
in lysis buffer and quantified for protein levels using a 
commercial assay (Bio-Rad, CA, USA). Western blot-
ting was performed according to standard procedures as 
previously described [33]. Protein samples (60  μg) were 
applied to sodium dodecyl sulfate (SDS) polyacrylamide 
gel (10–15%), electrophoresed under denaturing condi-
tions and electrotransferred onto nitrocellulose mem-
branes (Bio-Rad). Membranes were blocked with 3% BSA 
in Tris-buffer saline (TBS). Primary antibodies for phos-
phorylated and total ERK1/2, PPARγ, β ACTIN, GAPDH 
(Santa Cruz Biotechnology, Dallas, Texas, USA), PGC-1α 
(ABCAM, Cambridge, UK), SOD2 (ABCAM, Cam-
bridge, UK), and SIRT1 (Merck Millipore Corp. USA) 
were used in TBST with 3% BSA overnight at 4 °C. Dye 
680 or 800 secondary antibodies were added at a concen-
tration of 1:10,000 for 1 h at room temperature (LI-COR 
Biosciences, NE, USA). Detection was carried out with 
the LI COR Odyssey. Quantification of signals was car-
ried out with the Odyssey program. The ratio between 
the intensity of the band of the tested protein and the 
intensity of the corresponding ACTIN or GAPDH band 
was calculated for normalization/expression of results.
Nuclear cytoplasm extraction
Cardiac tissue (n = 4 in each group) was homogenized 
and the nuclear and cytoplasm fraction extracted using 
the NE-PER nuclear and cytoplasmic extraction kit 
(Thermo Scientific, IL, USA) according to the manufac-
turer’s instructions.
Rt‑PCR
Total RNA (n = 4 in each group) was purified from hearts 
using TRIzol (Ambion, Austin, TX, USA) as per manu-
facturer’s instructions. The quantity of total RNA was 
determined by OD260 measurements. cDNA was syn-
thesized from total RNA using the TaqMan High Capac-
ity cDNA Reverse Transcription Kit (Applied Biosystems, 
Foster City, CA, USA) according to the manufacturer’s 
protocol.
Quantitative real-time PCR analysis was performed 
using the step one plus system (Applied Biosystems, 
Foster City, CA, USA). The primers and TaqMan FAM 
probes were ordered from Applied Biosystems. All sam-
ples were normalized to an endogenous gene, mouse 
TATA-box.
Gene Assay ID








Serum thiobarbituric acid reactive substances
Malondialdehyde (MDA) level is commonly known 
as a marker of oxidative stress. MDA can be quanti-
fied through a controlled reaction with thiobarbituric 
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acid, generating ‘thiobarbituric acid reactive substances’ 
(TBARS). Thus, lipid peroxidation was determined (n = 4 
in each group) using the TBARS assay kit (Cayman 
Chemical, MI, USA) according to the manufacturer’s 
instructions.
SIRT and HDAC1/2 activity
SIRT and HDAC1/2 activity in the nuclear fraction of 
cardiac tissue samples (n = 4 in each group) were meas-
ured using an Universal SIRT activity assay kit (Abcam, 
Cambridge, UK) and a HDAC colorimetric assay/drug 
discovery kit (Enzo Life Sciences, NY, USA) according to 
the manufacturers’ instructions.
Cell culture
Rat hearts (Sprague–Dawley, 1–2 days old) were removed 
under sterile conditions and washed three times in phos-
phate-buffered saline (PBS) to remove excess blood cells. 
The hearts were minced and then gently agitated in a 
solution of proteolytic enzymes—RDB (Biological Insti-
tute, Ness-Ziona, Israel), which was prepared from fig 
tree extract. RDB was diluted 1:100 in  Ca2+ and  Mg2+ 
free PBS for a few cycles of 10  min each, as described 
previously [35]. Dulbecco’s modified Eagle’s medium 
(Biological Industries, Kibbutz Beit Haemek, Israel) con-
taining 10% horse serum was added to supernatant sus-
pensions containing dissociated cells. The mixture was 
centrifuged at 300 g for 5 min. The supernatant was dis-
carded, and the cells were resuspended. The suspension 
of the cells was diluted to 1.06 ×  106 cells/ml, and 1.5 ml 
of the suspension was placed in 35-mm plastic culture 
dishes, or 0.5  ml in 24 wells plates. The cultures were 
incubated in a humidified atmosphere of 5% CO2 and 
95% air at  37OC. Confluent monolayers exhibiting spon-
taneous contractions developed in culture within 2 days.
Experiments with EX‑527
Cultured cardiomyocytes were incubated with normal 
(17.5 mM) or high concentration of glucose (33 mM) for 
4  days. Glucose concentration of 17.5  mM is normally 
used for cardiomyocytes and was therefore considered as 
control. The SIRT 1 inhibitor EX-527 (10 µM) (Cayman 
Chemical, MI, USA) was added to the culture for 24 h.
In‑vitro ROS production measurement
ROS was detected using a 2′,7′-Dichlorofluorescin diac-
etate (DCF-DA) reagent (Sigma-Aldrich, St. Louis, 
MO,USA). This compound is an uncharged cell-perme-
able molecule. Inside cells, this probe is cleaved by non-
specific esterases, forming carboxydichlorofluoroscein, 
which is oxidized in the presence of ROS. Cells were 
loaded with 10 µM DCF-DA for 30 min at 37 °C and then 
washed. Fluorescence was monitored with a microplate 
fluorometer using wavelengths of 485/538 nm for excita-
tion/emission, respectively.
Statistical analysis
Animals were assigned to groups randomly. All values 
are expressed as mean ± SD. In the in vivo studies results 
were normalized to the WT group and in the in  vitro 
studies the result were normalized to the 17.5 mM glu-
cose control group. The statistical difference between the 
two groups was assessed using the 2-tailed student’s t 
test. To compare more than 2 groups, one way analysis of 
variance (ANOVA) with Duncan’s multiple comparison 
option was used. p < 0.05 was considered significant.
Results
Angiotensin II promotes development of metabolic 
dysfunction and diabetic cardiomyopathy
DM had no significant effect on murine cardiac struc-
ture and function up to the age of 4  months. Diabetic 
mice (db/db) had normal cardiac function, dimension 
parameters and heart weight (Table  1) which was not 
significantly different from untreated WT mice. AT sig-
nificantly (p < 0.05) increased blood pressure and heart 
weight in both WT and diabetic mice. AT treatment of 
db/db mice resulted in wall thickening and 10% reduc-
tion of LV diameter without change in systolic function 
(Table  1). In contrast, in WT mice, AT increased the 
LV dimension and impaired the systolic function with-
out wall thickening (Table 1). AT had no effect on blood 
glucose levels but elevated the level of serum choles-
terol and triglycerides in both WT and diabetic mice. 
Notably, blood lipids are already elevated in diabetic 
mice (Table  1). Histological staining demonstrated that 
AT promoted the formation of fibrotic tissue (p < 0.003) 
(Fig.  1A, B, D, E and M) and leukocyte infiltration 
(Fig. 1G, H, J, K). These pathological findings were more 
pronounced in the diabetic heart (p = 0.03, Fig. 1M).
CR attenuates the metabolic abnormalities 
and development of diabetic cardiomyopathy
In both lean and diabetic mice, CR led to a ~ 20% weight 
loss. CR attenuated the AT-induced hypertension but 
this was statistically significant only in diabetic mice 
(p < 0.004). High glucose levels in the diabetic mice were 
only moderately reduced after CR (24%). Both in lean and 
in diabetic mice the increase in lipid profile following AT 
was attenuated (~ 65%) (Table 1). The left ventricular FS 
increased concomitant with attenuation of left ventricu-
lar hypertrophy (Table  1). Histopathological sections 
indicated an absence of fibrosis (p < 0.002, Fig. 1C, F and 
M) and leukocyte infiltration in cardiac tissue of the CR 
groups (Fig. 1I, L).
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Effect of CR on the molecular markers of cardiomyopathy
Genes related to cardiac hypertrophy and heart failure 
ANP, BNP were elevated in mice treated with AT inde-
pendently of diabetes, and their expression was attenu-
ated after CR (Fig. 1O and Q). Genes related to cardiac 
remodeling of TGFβ, TNFα and MMP2 were elevated 
by either diabetes or AT and were reduced in CR-mice 
(Fig. 1N, P and R).
Effect of CR on metabolic signaling and SIRT activity
Phosphorylation of ERK1/2 is part of the stress signal-
ing in the heart. ERK1/2 was activated in diabetic mice 
independently of AT infusion. Its phosphorylation 
increased by twofold (p < 0.02) but was reduced by 70% 
(p < 0.05) due to CR (Fig.  2a). The cardiac expression of 
adiponectin was reduced by AT in both WT and dia-
betic mice. CR increased the expression of adiponectin 
by threefold (p < 0.04), (Fig. 2c). pAMPK was reduced in 
the AT-treated mice (p < 0.04) and was elevated following 
CR (p = 0.001) (Fig.  2f ). In diabetic mice, PPARγ levels 
were sevenfold higher compared to WT mice and were 
further elevated after AT treatment. CR reduced PPARγ 
levels (fivefold reduction) in the heart of db/db +AT mice 
indicating its modifying effect on cellular metabolism 
(Fig. 2b).
In WT mice, SIRT activity was reduced by 70% after 
AT treatment (p = 0.003). In db/db and db/db + AT mice, 
SIRT activity was reduced by 82 and 88% respectively 
compared to WT mice (p = 0.02). CR increased SIRT 
activity in db/db + AT mice by 65% (p < 0.05) (Fig.  2d). 
SIRT1 can affect chromatin remodeling and thus mod-
ulation of gene expression [36]. The suppression of 
SIRT activity in the diabetic mice resulted in ~ twofold 
(p < 0.04) elevation in HDAC 1/2 (histone deacetylase) 
activity that was prevented by CR (p = 0.002), (Fig. 2e).
CR reduced oxidative stress and increased levels of PGC‑1α
In order to clarify the effect of CR on oxidative stress 
and anti-oxidative defense, we measured MDA levels in 
the serum and found them to be significantly elevated 
in db/db + AT mice compared to WT mice (p = 0.01). 
CR reduced the levels of MDA in the serum (p < 0.03) 
(Fig.  3a). SIRT1 regulates PGC-1α thus activating anti-
oxidant defenses [37]. The level of mitochondrial fac-
tor PGC-1α mRNA levels were reduced by either AT or 
diabetes (p < 0.001). Following CR, PGC-1α levels were 
elevated (p < 0.0001) and were restored to WT levels 
(Fig. 3c). The PGC-1α protein levels were increased in the 
nuclear but not cytosolic fraction of CR-treated diabetic 
mice (Fig. 3b). These changes concurred with the level of 
antioxidant defenses represented by SOD2 protein levels 
(Fig. 3d).
SIRT1 controls PGC‑1α levels and is involved in cellular ROS 
levels
The relationships between SIRT1 and PGC-1α in 
response to hyperglycemic were tested in vitro. To exam-
ine the role of SIRT1 in glucose metabolism and oxidative 
Table 1 Metabolic and cardiac phenotype in AT treated mice
Values are mean±SD
IVS;d intra ventricular septum in diastole, IVS;s intra ventricular septum in systole, LVPW;d left ventricle posterior wall in diastole, LVPW;s left ventricle posterior wall in 
systole, LVESD left ventricle end systolic dimension, LVEDD left ventricle end diastolic dimension, FS fractional shortening, AST aspartate aminotransferase, ALT alanine 
aminotransferase
*p < 0.05 vs. WT, ^p<0.05 vs.WT+AT, #p<0.05 vs. db/db, &p<0.05 vs. db/db+ AT
WT WT + AT WT + AT + CR db/db db/db + AT db/db + AT + CR
IVS; d (mm) 0.8 ± 0.1 0.9 ± 0.1 0.8 ± 0.2 0.9 ± 0.1 1.1 ± 0.1# 1 ± 0.1&
IVS; s (mm) 1.2 ± 0.1 1.2 ± 0.2 1.4 ± 0.5 1.4 ± 0.2* 1.6 ± 0.2# 1.5 ± 0.3*
LVPW; d (mm) 0.9 ± 0.1 1 ± 0.1 0.8 ± 0.1^ 0.9 ± 0.1 1.1 ± 0.2# 0.9 ± 0.2&
LVPW; s (mm) 1.2 ± 0.1 1.1 ± 0.1 1.3 ± 0.1 1.2 ± 0.2 1.5 ± 0.3# 1.2 ± 0.3&
LVEDD (mm) 3.6 ± 0.7 4.2 ± 0.4* 3.5 ± 0.5^ 3.9 ± 0.2 3.5 ± 0.05# 4.1 ± 0.4&
LVESD (mm) 2.9 ± 0.2 3.3 ± 0.6 1.93 ± 0.8^ 2.6 ± 0.3* 2.4 ± 0.6* 2.5 ± 0.5
FS (%) 33 ± 14 21 ± 7* 46 ± 14^ 34 ± 7 30 ± 7 41 ± 10&
Body weight (g) 26 ± 3 25± 2 19 ±  1* 41 ± 10* 40 ± 5* 33 ± 7&
Heart weight (mg) 115 ± 2 148 ± 3* 97 ± 2^ 117 ± 2 163 ± 3# 139 ± 2&
Systolic blood pressure (mmHg) 95 ± 21 134 ± 29* 117 ± 13 99 ± 30 148 ± 15# 114 ± 11&
Glucose (mg/dL) 137 ± 44 111 ± 41 107 ± 43 617 ± 93* 658 ± 107* 531 ± 127&
AST (U/L) 62 ± 25 60 ± 11 60 ± 18 127 ± 53* 226 ± 149# 99 ± 21&
ALT (U/L) 126 ± 42 130 ± 30 127 ± 56 182 ± 134 281 ± 176* 117 ± 32&
Cholesterol (mg/dL) 79 ± 24 101 ± 22* 8 ± 70^ 112 ± 21* 199 ± 91# 118 ± 25&
Triglycerides (mg/dL) 124 ± 57 125 ± 25 22 ± 82^ 185 ± 66* 208 ± 75* 127 ± 35&
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stress we used cultured rat neonatal cardiomyocytes 
exposed to high concentration of glucose (33 mM). Ele-
vation of glucose levels led to increased cellular ROS 
production (p < 0.03) (Fig.  4A and C) and reduction in 
PGC-1α protein levels (p < 0.05, Fig.  4F and H). SIRT 1 
inhibition by EX-527 elevated ROS production (Fig.  4B 
and D). SIRT1 and PGC-1α levels were dramatically 
reduced (Fig.  5f–h). Cumulatively these results indi-
cate the pivotal role and the direct relationship between 
SIRT1 and PGC-1α protecting cardiomyocytes against 
oxidative stress which participates in the pathogenesis of 
diabetic heart disease.
Discussion
In the normal heart, insulin stimulates glucose uptake 
and oxidation. Insulin binding to its surface recep-
tor elicits a signaling cascade that includes activation of 
PI3 K, AKT and PKC leading to the translocation of glu-
cose transporters to the cardiomyocyte membrane thus 
facilitating glucose uptake. Insulin resistance in diabetic 
patients results in impaired cardiac glucose uptake and 
hyperglycemia, whereas cardiac FA uptake and metabo-
lism increase [38]. This initial switch towards FA utiliza-
tion elevates intracellular FA derivatives, such as MDA, 
which activate the PPARα/γ. Subsequently, there is an 
increase in ROS generation and oxidative damage in the 
mitochondria isolated from diabetic hearts. Diabetes 
is characterized by a decreased expression of oxidative 
phosphorylation genes. Many of these genes are regu-
lated by nuclear respiratory factor 2 (NRF2)-dependent 
transcription of antioxidant enzymes, such as superoxide 
dismutase (SOD), catalase, Heme Oxygenase -1 (HO-1), 
NAD (P) H, quinine oxidoreductase-1 and thioredoxin 
(Trx-1). When antioxidant defenses are insufficient to 
Fig. 1 CR attenuates fibrosis and inflammation in diabetic mice. Representive pictures of leukocytes infiltration and fibrotic tissue (arrows) that 
were observed in the heart of AT treated mice as seen by Masson’s trichrome (A–F) and Hematoxylin &Eosin (G–I) staining. The percentage of 
fibrotic area was calculated (M). *p < 0.05 vs. WT, ^p < 0.05 vs. WT + AT, &p < 0.05 vs. db/db + AT. n = 3 in each group. Values represent mean ± SD. CR 
reduced the cardiac mRNA levels of TGFβ (N), ANP (O), TNFα (P), BNP (Q), MMP2 (R). *p < 0.05 vs. WT, #p < 0.05 vs. db/db, &p < 0.05 vs. db/db + AT. 
n = 5 in each group. Values represent mean ± SD
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counteract ROS production, the excessive levels of ROS 
become cytotoxic [39]. Diabetic hearts are characterized 
by reduced AKT phosphorylation [40] and by decreased 
mitochondrial function [41] resulting in the overwhelm-
ing of the endogenous protective mechanisms and defec-
tive responsiveness to stress.
In this study we examined the ability of CR to alleviate 
diabetic cardiomyopathy and to identify the key pathways 
involved in CR mediated cardioprotection. CR is consider 
to be metabolic protective, however there are conflict-
ing report as to its effects on the heart in diabetes [42]. 
There are numerous pathways involved in different mod-
els of cardiomyopathy [43]. The renin angiotensin system 
(RAS) plays a fundamental role in the pathophysiology of 
diabetes and its complications, as a result angiotensin-
converting enzyme (ACE) inhibitors are widely used in 
treating diabetic patients [44]. Cardiac hypertrophy is 
mediated in part by RAS and TGF-β which have a central 
role in cardiac remodeling. Diabetic mice 4  months old 
did not develop cardiac hypertrophy or fibrosis. There-
fore, we used AT in our model system to enhance and 
aggravate cardiomyopathy that otherwise only occurs in 
obese diabetic mice with aging. This concentration was 
reported previously to induce cardiomyopathy mainly 
through its profibrotic effects [2, 12]. AT through AT1R 
stimulates TGF-β which promotes fibroblast prolif-
eration, ECM deposition and myocyte hypertrophy [45] 
independent of its effects on blood pressure [12]. TGF-β 
induction precedes the development of myocardial fibro-
sis and ECM production [46]. Noteworthy, ERK1/2 and 
TGF-β were elevated in the diabetic mouse independ-
ent of AT, indicative of cellular signaling that precedes 
the development of cardiomyopathy. In addition to its 
effects on myocardial remodeling AT contributed to 
the dyslipidemia in db/db mice and increased PPARγ 
expression. These changes may underlie additional detri-
mental effects such as increased lipid accumulation and 
atherosclerosis [47], which are often observed in diabetic 
patients.
CR reduced body weight and prevented the develop-
ment of left ventricle hypertrophy. The cardioprotection 
afforded by CR was unrelated to glucose levels which 
were only mildly reduced. A possible explanation is that 
the leptin signaling, which is abolished in db/db mice, is 
Fig. 2 CR alters cellular metabolism and gene expression regulation. Representative Western blot for ERK1/2 phosphorylation and densitometry 
analysis of ERK1/2 normalized to GAPDH indicating attenuation in ERK overactivation following CR. n = 4 in each group, *p < 0.05 vs. WT, &p < 0.02 vs. 
db/db + AT group (a). Representative Western blot for PPARγ and densitometry analysis of PPARγ normalized to β actin showing reduction in PPARγ 
protein levels following CR. n = 4 in each group, *p < 0.03 vs. WT, #p = 0.02 vs. db/db, &p < 0.001 vs. db/db + AT group (b). ADIPONECTIN mRNA levels 
were measured in the cardiac tissue (c). SIRT (d) HDAC1/2 (e) activity were measure in the nuclear fraction from WT and db/db mice hearts. Cardiac 
protein levels of pAMPK relative to total AMPK western blot and densitometry (f). *p < 0.05 vs. WT, #p < 0.05 vs. db/db, &p < 0.05 vs. db/db + AT group, 
n = 4 in each group. Values represent mean ± SD
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important in glucose homeostasis that is independent of 
the pathways by which leptin regulates food intake and 
body weight [48]. Furthermore, this proves that CR has 
a direct effect on cardiomyocytes beyond glycemic con-
trol. PPARγ is a regulator of lipid utilization and PPARγ 
agonists are used clinically as antidiabetic drugs [49]. 
However, a PPARγ activator, like thiazolidinediones, 
is associated with side effects such as edema and body 
weight gain [50, 51]. It is suggested that using a PPARδ 
specific ligand can be a more beneficial therapeutic 
approach to treat the diabetic heart [52]. CR reduced 
cardiac PPARγ levels, concomitantly attenuating cardiac 
lipotoxicity which is one of the mechanisms responsible 
for diabetic cardiomyopathy and heart failure [53].
In isolated cardiomyocytes AT increased ERK1/2 phos-
phorylation in a  Ca+ dependent manner, which led to the 
upregulation of ANP [54]. These effects may be direct, 
via activation of ERK-1/ERK-2-dependent pathway, 
increasing the local production of TGF-β [55]. Cardiac 
hypertrophy is associated with alterations in gene expres-
sion involving epigenetic changes [56]. The development 
of cardiac hypertrophy in our mouse model was associ-
ated with increased HDAC activity and ERK phosphoryl-
ation. It was attenuated by CR (Fig. 2).
Sirtuins are NAD+ -dependent, and, as such, their acti-
vation is regulated by the cellular metabolic state [57]. 
One of the key metabolic pathways is activation of sir-
tuin 1 (SIRT1) resulting in increased levels of adiponectin 
and stimulation of mitochondrial biogenesis and anti-
oxidant defenses. SIRT1 regulates many essential cellular 
processes including survival, apoptosis, inflammation, 
stress resistance, cell growth, metabolism and senes-
cence and prevent mitochondrial dysfunction [58, 59]. 
The expression of SIRT1 was shown to be reduced in a 
mouse model of diabetic cardiomyopathy and resulted in 
both compromised insulin signaling and mitochondrial 
dynamic abnormity. Whereas deletion of SIRT1 expres-
sion in the heart contributed to phenotypes resembling 
Fig. 3 CR alleviates oxidative stress through the activation of PGC‑1α. MDA levels in the serum were measured using TBARS kit, n = 4 in each group 
(a). PGC‑1α protein levels in the cytoplasmic (cyto) and nuclear (nuc) fractions (b) as well as mRNA expression levels (c) were measured in the 
cardiac tissue (c). Cardiac SOD2 protein levels (d). n = 4 in each group, *p < 0.05 vs. WT, #p < 0.05 vs. db/db &p < 0.05 vs. db/db + AT. Values represent 
mean ± SD
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Fig. 4 SIRT1 is required for the expression of PGC‑1α. Neonatal Rat cardiomyocytes were exposed to 17.5 and 33 mM glucose and treated with the 
SIRT1 inhibitor EX‑527. Cells were stained with DCF‑DA (A–D) and fluorescence was measured using fluorimeter (E). Representative western blots 
for SIRT1 and PGC‑1α for cell treated with EX‑527 (F). Densitometry analysis for SIRT1 (G) and PGC‑1α (H). Results were normalized to the group 
exposed to 17.5 mM glucose. *p < 0.04 vs.17.5 mM control, &p < 0.02 vs. 33 mM control, n = 4 in each group. Values represent mean ± SD
Fig. 5 Schematic description of the cellular signaling involved in the development of cardiomyopathy in diabetes and proposed mechanism for 
the effect of CR on the diabetic heart. The energetic dysfunction in diabetes manifested by increased FFA in the heart together with elevation 
in local and systematic production of Angiotensin leads to mitochondrial dysfunction, oxidative stress and inflammation. In the diabetic heart 
PARP‑1 and ERK are elevated, promoting the development of cardiac hypertrophy. CR elevates adiponectin, pAMPKand SIRT‑1 levels. This leads to 
the activation of both PGC‑1α and improved mitochondrial function, alleviate the oxidative stress and reduce inflammation by CR ameliorating 
cardiomyopathy
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diabetic cardiomyopathy in  vivo and to mitochondrial 
dysfunction through PGC1-α in vitro [60, 61]. Thus Sirt1 
activators such as resveratrol can used as CR mimetics to 
reduce diabetic cardiomyopathy.
Several signaling pathways converge at the level of the 
mitochondria therefore accounting for cardiac mito-
chondrial dysfunction in diabetes. AMPK is a key meta-
bolic regulator activated during exercise and weight loss. 
Among the many activities of AMPK are transcription 
and phosphorylation of the co-activator PGC-1α, which 
induces mitochondrial transcription factors (e.g. mtTFA) 
augmenting both mitochondrial content and cellular 
metabolic oxidative capacity. Yet, PGC-1α is not acti-
vated until it is deacetylated by SIRT1 [62, 63]. Dysfunc-
tion in this pathway has been implicated as a contributing 
factor in such metabolic disorders as the metabolic syn-
drome and DM2 [64]. Additionally, there is a direct 
relationship between SIRT1 and NO production and 
vascular function in DM2 patients [65]. Oxidative stress 
plays a pivotal role in the development of obesity and the 
pathogenesis of diabetes [8]. PGC-1α is a master regula-
tor of mitochondrial biogenesis. PGC-1α is activated by 
both SIRT1 through deacetylation and by AMPK through 
phosphorylation, resulting in improved mitochondrial 
function [26, 27]. Mitochondrial malfunction associated 
with insulin resistance is a prime contributing factor for 
DCM. Forkhead box transcription factor 1 (FOXO1) is 
involved in the integration of mitochondrial function 
with insulin signalling. Elevated FOXO1 levels in insulin 
resistant states disrupt mitochondrial electron transport 
chain, thereby promoting impaired oxidative respira-
tion. In addition, FOXO1 is involved in the regulation of 
the mitochondrial biogenesis by affecting the expres-
sion of genes regulating mitochondrial fission and fusion 
through SIRT1/PGC-1α pathway [66]. Another novel fac-
tor regulation PGC-1α activity is Extracellular signal-reg-
ulated protein kinase 5 (Erk5) which is lost in the hearts 
of obese/diabetic animal models [41].
We have previously shown that activation of PGC-1α 
reduced mitochondrial ROS and prevented adipogenesis 
in adipocytes [67]. EX-527 mediated inhibition of SIRT1 
elevated ROS production while SIRT1 and PGC-1α levels 
were dramatically. In higher glycemia, PGC1 α inhibition 
induced increased mitochondrial fragmentation and ROS 
generation [68]. In this study we show that the cardiopro-
tective effect of CR in diabetic mice involves increased 
expression of PGC-1α and SIRT1. In cardiomyocytes, 
pharmacological inhibition of SIRT1 was followed by 
the decreased expression of PGC-1α and increased ROS 
production. We conclude that the increased expression 
of SIRT1 and PGC-1α is central to rebuffing oxidative 
stress caused by hyperglycemia and thus a therapeutic 
approach to cardiac protection.
We have previously shown that activation of PGC-1α 
reduced mitochondrial ROS in adipocytes through 
the induction of HO-1 [67] and its downstream targets 
constituting essential antioxidant defense mechanisms. 
HO-1 has been directly implicated in the protection of 
the diabetic heart [69, 70]. Silencing PGC-1α by the use 
of antisense nucleotides prevented increased levels of 
HO-1 [67]. We conclude that the SIRT1-PGC-1α-HO-1 
axis is pivotal in order to cope with oxidative stress 
caused by hyperglycemia and has an important role to 
play in protecting the diabetic heart.
While the field of pharmacological therapies contin-
ues to expand, efforts to facilitate weight loss have had 
limited success. In the present study we examined the 
cellular mechanism by which CR protects the diabetic 
heart. A new class of drugs that mimic the cellular and 
metabolic of exercise or calorie restriction would lead to, 
we believe, better patient compliance than a true calorie 
restriction.
Understanding the fundamental and biochemical 
processes to prevent adverse cardiac remodeling that 
occur in diabetic cardiomyopathy is crucial for develop-
ing novel therapeutic approaches to treat heart failure, 
a major source of morbidity and mortality in diabetic 
patients and a major drain of health care costs and 
resources.
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